NDRA
ENDRA Life Sciences Inc.NASDAQHealthcare$4.69+0.86%ClosedMarket Cap: $3.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.65
P/S
0.00
EV/EBITDA
-0.59
DCF Value
$-0.12
FCF Yield
-145.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-496.9%
ROA
-182.4%
ROIC
-178.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $0.00 | $-3.2M | $-3.26 | — |
| FY 2025 | $0.00 | NaN% | $0.00 | $-7.0M | $-8.93 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.4M | $-1.6M | $-2.10 | — |
| Q2 2025 | $0.00 | -Infinity% | $-1.3M | $-1.2M | $-1.71 | — |
| Q1 2025 | $0.00 | -Infinity% | $-1.5M | $-1.0M | $-1.86 | — |
| Q4 2024 | $0.00 | -Infinity% | $-4.3M | $-4.1M | $-7.73 | — |
| FY 2024 | $0.00 | NaN% | $-10.8M | $-11.5M | $-10.25 | — |
| Q3 2024 | $0.00 | NaN% | $-1.5M | $-2.4M | $-2.10 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.2M | $-2.2M | $-1.31 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.8M | $-2.8M | $-1.63 | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.5M | $-1.5M | $-0.85 | — |
| FY 2023 | $0.00 | -Infinity% | $-10.5M | $-10.1M | $-5.89 | — |